The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.
Also called NCT02558231
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 247 participants
- Sponsor
- Registry
-
NCT02558231
-
- Other papers using this trial's data
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02558231. Randomized; quadruple masking; primary purpose treatment. Start 2016-05-01 (actual); primary completion 2019-08-29 (actual). Results posted on 2020-09-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
- Acronym
- TRITON
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Macitentan
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Selexipag
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct02558231- Content hash
12053417bc38169c675d5ab60221360c6ab41ae21e7e769edcf26f5236f7b6bb